GlassScriptPhysician profile
Douglas A Schultz
NPI 1124022041
$1,820.43
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $118 · 2022: $183 · 2023: $372 · 2024: $500 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $309.19 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $304.47 | 2019-2025 | |
| Corium, LLC | $271.84 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $213.41 | 2019-2025 | Bexsero, Penmenvy |
| Sanofi Pasteur INC. | $95.05 | 2023-2025 | |
| Cranial Technologies, INC | $89.15 | 2024-2025 | Doc Band |
| Seqirus USA INC | $87.42 | 2022-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $69.89 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $51.44 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $50.59 | 2022-2025 | Qelbree |
| Alk-Abello, INC | $41.53 | 2023-2025 | Neffy, Grastek, Ragwitek |
| Ironshore Pharmaceuticals INC. | $41.19 | 2019 | |
| Biomarin Pharmaceutical INC. | $39.70 | 2023-2024 | |
| Exeltis, USA INC. | $35.63 | 2022-2024 | Slynd |
| Kaleo, INC. | $28.71 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.23 | 2024 | Aptima |
| Alexion Pharmaceuticals, INC. | $19.97 | 2024 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2019 | |
| Sobi, INC | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.